Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas (Bretuximab) (NCT02388490)
This is an open-label, non-randomized, multi-center, phase II trial of brentuximab vedotin (also known as SGN-035) to evaluate ORR primarily in patients with Epstein-Barr virus (EBV)- and CD30-positive lymphomas.
This trial is sponsored by Seoul National University Hospital. 
- Condition: Lymphoma
- Phase: II
- Estimated Enrollment: 25
- Start: April 2015
- Estimated Completion: June 2017
- Last verified: March 2015
Last Editorial review: July 2, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.